Evidence map›Paper›PMID 26884886›Full record

ArticleInternational journal of clinical and experimental pathology2015

Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall.

Caterina Chiappetta, Chiara Puggioni, Eugenio Lendaro, Jessica Cacciotti, Roberto Zaralli, Giovanna Migliore, Paola Bellardini, Vincenzo Petrozza, Carlo Della Rocca, Claudio Di Cristofano

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Caterina ChiappettaUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Chiara PuggioniUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Eugenio LendaroUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Jessica CacciottiUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Roberto ZaralliUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Giovanna MiglioreUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Paola BellardiniScreening Unit, Local Health Unit of Latina Italy.
Vincenzo PetrozzaUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Carlo Della RoccaUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Claudio Di CristofanoUOC of Pathology, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome Polo Pontino, I.C.O.T, Latina, Italy.
Ospedale di Latisana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With cervical cancer screening the choice of 1-year as a period of follow-up in positive high-risk HPV women without cytological lesions is still under discussion. We evaluated the management of these women and the role of HPV genotyping test. We did a cervical cancer screening study of women aged 35-64 with primary high-risk HPV test. Women positive for high-risk HPV with negative cytology were followed-up after 1 year. In this study we selected women with high-risk HPV+/PapTest- resulted high-risk HPV+ at recall and performed the PapTest and HPV genotyping test. The detection rate of squamous high grade (CIN2+) relative to the total screened cohort was 2.1‰, and it was 0.2‰ at the 1-year recall. The colposcopy performed in women referred at the 1-year recall accounted for 48.8% of the total (baseline + 1-year recall), and 84.3% of these women had no cytological lesions. The most frequent hr-HPV genotype detected was HPV16 and 66.7% of co-infections were due to HPV16 and HPV18. 54.5% of women presented a persistent infection at 1-year recall with the same HPV subtype, 50% of persistent infections was due to HPV16 and 16.7% of these were determined to be CIN2+ histological lesions. Our data show that it may be useful to extend the period of follow-up for women hr-HPV+/PapTest- so as to reduce the number of unnecessary colposcopies due to the transitory infections and that the genotyping test could help to identify the persistent infections in which HPV16 is involved.

Indexed as

Human Papillomavirus DNA TestsPapanicolaou TestAdultCase-Control StudiesColposcopyDNA, ViralFemaleFollow-Up StudiesGenotypeHuman papillomavirus 16Human papillomavirus 18HumansMiddle AgedPapillomavirus InfectionsPredictive Value of TestsRisk FactorsDNA, ViralCervical cancerfollow-upgenotypingHPVPapTestscreening

Identifiers

PMID26884886
PMCPMC4730099
OpenAlexW2411575212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.